Dolutegravir: a new option for HIV treatment - Wikidata - awgldk - TriplyDB

Dolutegravir: a new option for HIV treatment

Dolutegravir: a new option for HIV treatment

http://www.wikidata.org/entity/Q58290460

about

Dolutegravir: a new option for HIV treatment

http://www.wikidata.org/entity/Q58290460

description

article

@en

im September 2014 veröffentlichter wissenschaftlicher Artikel

@de

wetenschappelijk artikel

@nl

наукова стаття, опублікована у вересні 2014

@uk

name

Dolutegravir: a new option for HIV treatment

@en

Dolutegravir: a new option for HIV treatment

@nl

type

label

Dolutegravir: a new option for HIV treatment

@en

Dolutegravir: a new option for HIV treatment

@nl

prefLabel

Dolutegravir: a new option for HIV treatment

@en

Dolutegravir: a new option for HIV treatment

@nl

P1433

Q58290460-BA5EB1DF-3F4F-4838-B0B0-210A6D2DFE75

P1476

Q58290460-FB74DEE5-0C11-422B-8C15-322305F95858

P2093

Q58290460-8A2A5A64-066E-4739-A75D-372E262004F8

P2860

Q58290460-0C7C5202-EC3F-4E40-B244-4A9E6170E244

Q58290460-0D0EFB28-291C-4549-97F4-F63DDD9DFA80

Q58290460-1089B7C6-6163-40EF-9008-1EDC20515ABE

Q58290460-11427907-7FB8-4FFD-BB9C-5C784606A95F

Q58290460-1311619F-4B5D-48BC-9491-A40E8E862588

Q58290460-1570D602-8370-44C2-B2E7-2D0A8DCB8CF1

Q58290460-18E06ACA-20E8-49B3-B8DB-D4F888419332

Q58290460-1B7A74C4-EFC2-45B5-881B-EDE256BF2D13

Q58290460-1E3DFFB9-C4EA-420A-9B00-366080D008E5

Q58290460-2403003D-3075-4718-ADA5-A34B9CC055DE

P304

Q58290460-A288787A-99EB-4A62-823D-AA491F01B42B

P31

Q58290460-3424B91B-7A17-4020-8276-A81E6F7C3742

P356

Q58290460-65AE824C-D50D-47BB-B36B-EAE8BFE0DF92

P433

Q58290460-4CC78295-7AE7-455B-8EF3-4DAE56068EE8

P478

Q58290460-885A665E-ABC2-48D9-8E7F-B55AF29D323C

P50

Q58290460-97D07880-347D-4BA4-AE8A-1F6EE90F44B5

Q58290460-F9C1438D-9A63-4AD8-A03E-2A2147943884

P577

Q58290460-18493585-E014-476C-B1CC-C5BA5E0D3BFB

P356

P1433

Future Virology

P1476

Dolutegravir: a new option for HIV treatment

@en

P2093

Alessia Carbone

http://www.w3.org/2001/XMLSchema#string

P2860

Life expectancy of recently diagnosed asymptomatic HIV-infected patients approaches that of uninfected individuals

Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies

HIV-1 integrase inhibitor resistance and its clinical implications

Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells

Pharmacokinetics and safety of S/GSK1349572, a next-generation HIV integrase inhibitor, in healthy volunteers.

Dolutegravir in antiretroviral-experienced patients with raltegravir- and/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 study

Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING Study.

Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial.

Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study.

Effect of atazanavir and atazanavir/ritonavir on the pharmacokinetics of the next-generation HIV integrase inhibitor, S/GSK1349572.

P304

801-810

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2217/FVL.14.68

http://www.w3.org/2001/XMLSchema#string

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

9

http://www.w3.org/2001/XMLSchema#string

P50

Antonella Castagna

Adriano Lazzarin

P577

2014-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime